| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 8,754,198
- Publication Date: June 17, 2014
- Appl. No: 13/519408
- Application Filed: January 05, 2011
- Assignees: University of Ljubljana (Ljubljana, SI), Institute Jozef Stefan (Ljubljana, SI), Labena d.o.o. (Ljubljana, SI)
- Claim: 1. A gene construct coding for a polypeptide comprising a secretion signal peptide, wherein said secretion signal peptide is a peptide sequence selected from LEISSYCDA (SEQ ID No: 13), LQVDDIPSA (SEQ ID No: 15) and LGISSTCNA (SEQ ID No: 16), a TNFα binding domain and surface attachment domain for attachment to the surface of a lactic acid bacterium, said TNFα binding domain and said surface attachment domain being separated by a spacer region, said gene construct being under the control of a suitable promoter, wherein said TNFα binding domain is a TNFα binding affibody.
- Claim: 2. A gene construct according to claim 1 , wherein said secretion signal peptide is a signal peptide of Usp45 or of a homologue having 95% sequence identity to Usp45.
- Claim: 3. A gene construct according to claim 1 , wherein said surface attachment domain comprises 1 to 6 LysM repeats.
- Claim: 4. A gene construct of claim 1 , said construct coding for the protein sequence (a) of any one of SEQ ID NO:6 to SEQ ID NO: 10, or (b) for a sequence which is at least 95% identical to any one of said sequences under (a).
- Claim: 5. A protein construct encoded by a gene construct of claim 1 .
- Current U.S. Class: 536/234
- Patent References Cited: 7993848 August 2011 Herne ; 2007/0276124 November 2007 Turner et al. ; 2008/0274084 November 2008 Rottiers et al. ; 2010/0310514 December 2010 Cho et al. ; 1 477 802 November 2004 ; 97/14806 April 1997 ; 00/23471 April 2000 ; 2007/025977 March 2007
- Other References: Hugot et al., “Etiology of the inflammatory bowel diseases”, Int J Colorectal Dis., 14, 1999, pp. 2-9. cited by applicant ; Cho , “The genetics and immunopathogenesis of inflammatory bowel disease”, Nature Reviews/Immunology, vol. 8, Jun. 2008, pp. 458-466. cited by applicant ; Schwartz et al., “Optimizing Conventional Therapy for Inflammatory Bowel Disease”, Current Gastroenterology Report, 10, 2008, pp. 585-590. cited by applicant ; Old, “Tumor Necrosis Factor (TNF)”, Science Magazine, vol. 230, 1985, pp. 630-632. cited by applicant ; Sandborn et al., “Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and Safety”, Inflammatory Bowel Diseases, 1999, pp. 119-133. cited by applicant ; de Silva et al., “TNFα in stool as marker of intestinal inflammation”, The Lancet, vol. 340, 1992, p. 372. cited by applicant ; Worledge et al., “Oral Administration of Avian Tumor Necrosis Factor Antibodies Effectively Treats Experimental Colitis in Rats”, Digestive Diseases and Sciences, vol. 45, No. 12, Dec. 2000, pp. 2298-2305. cited by applicant ; Nygren, “Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold”, The FEBS Journal, 275, 2008, pp. 2668-2676. cited by applicant ; Le Loir et al., “Signal Peptide and Propeptide Optimization for Heterologous Protein Secretion in Lactococcus lactis”, Applied and Environmental Microbiology, vol. 67, No. 9, Sep. 2001, pp. 4119-4127. cited by applicant ; International Search Report for corresponding International Application No. PCT/EP2011/000019 dated Mar. 29, 2011. cited by applicant ; Written Opinion of the International Searching Authority for corresponding International Application No. PCT/EP2011/000019 dated Mar. 29, 2011. cited by applicant
- Primary Examiner: Shafer, Shulamith H
- Attorney, Agent or Firm: Renner, Otto, Boisselle & Sklar, LLP
|
